Targeting potential of antibody conjugates.
Although the use of conjugates of enzymes has been considered, their use has not been very actively pursued. Much more interest has focused on the possibilities offered by the use of toxins, their subunits or of ribosome inhibitors. Conjugates of holotoxin which were very active and specific in vitro have been prepared. High in vivo activity and some specificity together with reduced whole body toxicity has been described. When A chain subunits or ribosome inhibiting proteins are used, the results are more mixed. Some very active and specific conjugates are known but others have relatively low activity. The reasons for this may be associated with the particular antigen to which the antibody component is directed, the nature of the A chain or inhibitor and the type and physiological state of the target cell. Application to man seems likely in the first instance to involve the removal of undesirable cells from bone marrow transplants.
D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D000906:Antibodies / Q000008:administration & dosage* / Q000378:metabolism; D000937:Antigen-Antibody Reactions; D000970:Antineoplastic Agents / Q000008:administration & dosage; D055598:Chemical Phenomena; D002621:Chemistry; D004798:Enzymes / Q000008:administration & dosage; D006801:Humans; D037102:Lectins / Q000008:administration & dosage; D008970:Molecular Weight; D009928:Organ Specificity; D004364:Pharmaceutical Preparations / Q000008:administration & dosage*; D011868:Radioisotopes / Q000008:administration & dosage; D014118:Toxins, Biological / Q000008:administration & dosage
D000900:Anti-Bacterial Agents; D000906:Antibodies; D000970:Antineoplastic Agents; D004798:Enzymes; D037102:Lectins; D004364:Pharmaceutical Preparations; D011868:Radioisotopes; D014118:Toxins, Biological